$MRK

Immutep gains FDA orphan drug designation for eftilagimod alfa in soft tissue sarcoma, with Phase II trial results exceeding efficacy targets by 47%.

Mestag Therapeutics' FAP-targeted bispecific antibody MST-0312 selected for late-breaking AACR presentation in April 2026, with Phase 1 trials expected to begin mid-year.

Revolution Medicines surges 40% after Phase 3 trial shows daraxonrasib doubles survival in metastatic pancreatic cancer versus chemotherapy.

CSPC market projected to surge from $5.14B (2025) to $11.75B (2036), driven by aging populations, new drug approvals, and emerging therapies.

Epitopea appoints Dr. Lisa Butterfield, immuno-oncology expert, to Scientific Advisory Board to advance RNA-based cancer immunotherapies.

Bristol Myers Squibb trades at attractive 9.5x forward P/E with 4.2% yield and 17 years of dividend hikes, but faces revenue declines and patent expiration risks.

Sun Pharma finalizes $12B binding offer for Organon, marking India's largest overseas pharma acquisition amid industry consolidation.

Crohn's Disease drug market projected to grow 45% to $13.8B by 2032, driven by eight new therapies with novel mechanisms of action reshaping competition.

Merck cut its Terns Pharmaceuticals offer to $53/share from $61 following disappointing TERN-701 trial data, with a competing bidder also withdrawing its offer.

Merck stock fell 3.12% Tuesday despite announcing a $53-per-share acquisition of Terns Pharmaceuticals, pressured by broader market decline and healthcare sector weakness.

Evaxion completes Phase 2 extension of personalized cancer vaccine EVX-01 with 75% response rate and 92% durability at two years.

Merck acquires Terns Pharmaceutical for $6.7B to expand cancer pipeline with oral BCR-ABL1 inhibitor, targeting $70B commercial opportunity by mid-2030s.

Adagene reports 29% response rate for ADG126 in colorectal cancer with improved safety profile. Company maintains $74.5M cash reserves extending runway into early 2028.

Merck partners with Infinimmune for next-gen antibody drugs, gaining exclusive rights to candidates from AI-powered platform with up to $838M in potential milestone payments.

Schwab's Dividend ETF added UnitedHealth and Abbott while removing AbbVie, boosting healthcare allocation to 18.9% and increasing average dividend growth rates.

Esophageal cancer market projected to grow 44% to $2.37B by 2030 at 9.5% CAGR, with Pfizer, Roche, and Merck dominating through precision oncology and immunotherapy innovations.

Merck agrees to acquire Terns Pharmaceuticals for $6.7B to strengthen pipeline before Keytruda's 2028 patent expiry, but analysts suggest competing bids may emerge.

Merck acquires Terns Pharmaceuticals for $6.7 billion to gain TERN-701, a novel leukemia treatment, at 31% premium valuation.

Merck pursues $6B acquisition of Terns Pharma to strengthen oncology pipeline as Keytruda faces patent expiration amid broader $320B industry revenue cliff.

Quotient Therapeutics and Merck partner on IBD drug discovery, with Quotient receiving $20M upfront and up to $2.2B in milestones.